P01371078A01
The_DD cytogenetic_JJ hallmark_NN of_II chronic_JJ myelogenous_JJ leukemia_NN (_( CML_NN )_) is_VBZ the_DD Philadelphia_NN chromosome_NN (_( Ph1_NN )_) ,_, which_PNR reflects_VVZ a_DD chromosomal_JJ translocation_NN t_NN (_( 9_MC ;_: 22_MC )_) and_CC a_DD rearrangement_NN of_II the_DD ABL_NN and_CC bcr_NN genes_NNS ._.
P01482658A05
Of_II the_DD remaining_VVGJ 13_MC PCR-positive_JJ patients_NNS ,_, only_RR one_MC (_( 8_MC %_SYM )_) relapsed_VVD after_II 23_MC months_NNS ;_: the_DD other_JJ 12_MC were_VBD alive_JJ and_CC still_RR in_II remission_NN after_II a_DD median_JJ follow-up_NN of_II 16+_MC months_NNS (_( ranging_VVG 5+_MC to_II 29+_MC months_NNS )_) ._.
P01518306A02
The_DD relationship_NN between_II the_DD fusion_NN pattern_NN of_II BCR_NN /_SYM ABL_NN mRNA_NN and_CC the_DD clinical_JJ outcome_NN was_VBD also_RR analysed_VVN ._.
P01674385A05
Twelve_MC of_II these_DD patients_NNS have_VHB remained_VVN in_II remission_NN by_II morphologic_JJ and_CC karyotypic_JJ criteria_NNS from_II 16.6_MC to_II 63.7_MC months_NNS following_VVG BMT_NN ._.
P01728316A09
The_DD pattern_NN of_II bcr_NN /_SYM abl_NN PCR_NN detection_NN after_II transplant_NN may_VM aid_VVB in_II the_DD development_NN of_II trials_NNS designed_VVN to_TO reduce_VVI the_DD risk_NN of_II relapse_NN ,_, or_CC allow_VVB for_II early_JJ intervention_NN in_II patients_NNS who_PNR fail_VVB to_TO clear_VVI the_DD malignant_JJ clone_NN ._.
P01763047A04
These_DD data_NNS show_VVB that_CST murine_JJ CML_NN can_VM result_VVB from_II retroviral_JJ transfer_NN of_II the_DD bcr_NN /_SYM abl_NN gene_NN into_II pluripotent_JJ hematopoietic_JJ stem_NN cells_NNS ,_, that_CST infected_VVNJ clones_NNS repopulate_VVB poorly_RR after_II adoptive_JJ transfer_NN ,_, and_CC that_CST these_DD clones_NNS can_VM give_VVB rise_NN to_II acute_JJ leukemia_NN ,_, reflecting_VVG evolution_NN to_II a_DD phase_NN resembling_VVG blast_NN crisis_NN in_II the_DD human_NN disease_NN ._.
P01824268A06
Patients_NNS in_II whom_PNR PCR_NN positivity_NN was_VBD sustained_VVN over_II time_NN had_VHD a_DD higher_JJR probability_NN of_II CML_NN relapse_NN than_CSN patients_NNS in_II whom_PNR PCR_NN was_VBD intermittently_RR negative_JJ (_( P_NN =_SYM .0095_MC ,_, log_NN rank_NN test_NN )_) ._.
P01932296A03
Eight_MC of_II 16_MC patients_NNS were_VBD negative_JJ by_II two-step_NN PCR_NN 1-39_MC months_NNS after_II BMT_NN ,_, suggesting_VVG an_DD elimination_NN of_II Ph-positive_JJ cells_NNS or_CC a_DD decrease_NN below_II the_DD threshold_NN of_II detection_NN ._.
P01932752A08
However_RR ,_, mRNA_NN processing_VVGN in_II children_NNS may_VM preferentially_RR splice_VVB Mbcr_NN exon_NN 2_MC to_II ABL_NN exon_NN II_MC ._.
P01961034A09
The_DD second_JJ cluster_NN occurred_VVD within_II two_MC sub-zones_NNS that_PNR spanned_VVD an_DD Alu_NN sequence_NN ,_, and_CC 90_MC %_SYM of_II this_DD cluster_NN exhibited_VVD b3-a2_NN spliced_VVNJ RNA_NN ._.
P02013978A06
In_II two_MC of_II these_DD three_MC patients_NNS ,_, samples_NNS were_VBD available_JJ from_II the_DD time_NN of_II initial_JJ diagnosis_NN ._.
P02032243A08
Also_RR ,_, one_MC chronic_JJ phase_NN patient_NN analyzed_VVN on_II three_MC separate_JJ occasions_NNS lacked_VVD P210_NN BCR-ABL_NN and_CC exhibited_VVD only_RR the_DD Mr_NN 190,000_MC form_NN ._.
P02065312A03
The_DD presence_NN of_II a_DD rearrangement_NN involving_VVG the_DD major_JJ breakpoint_NN cluster_NN region_NN (_( mbcr_NN )_) on_II chromosome_NN 22_MC was_VBD confirmed_VVN by_II Southern_NN blotting_VVGJ techniques_NNS ._.
P02157692A02
Molecular_JJ analysis_NN was_VBD performed_VVN on_II 25_MC patients_NNS with_II Ph-positive_JJ CML_NN using_VVG 2_MC breakpoint_NN cluster_NN region_NN (_( bcr_NN )_) probes_NNS within_II the_DD M-BCR-1_NN DNA_NN sequences_NNS ,_, and_CC two_MC of_II them_PN did_VDD not_RR contain_VVB either_CC detectable_JJ rearranged_VVNJ DNA_NN homologous_JJ to_II the_DD 5_MC '_SYM side_NN bcr_NN probe_NN or_CC ABL-related_VVNJ fusion_NN mRNA_NN ._.
P02197265A04
From_II molecular_JJ studies_NNS ,_, it_PN seemed_VVD that_CST Ph-_NN CML_NN with_II features_NNS of_II true_JJ CML_NN always_RR have_VHB the_DD bcr_NN rearrangement_NN ,_, while_CS Ph-_NN patients_NNS ,_, lacking_VVG such_DD rearrangement_NN ,_, have_VHB atypical_JJ forms_NNS of_II CML_NN ._.
P02198962A03
Furthermore_RR ,_, breakpoints_NNS in_II this_DD intron_NN clustered_VVD in_II three_MC regions_NNS ,_, approximately_RR 30_MC +/-_SYM 5_MC ,_, 100_MC +/-_SYM 13_MC ,_, and_CC 135_MC +/-_SYM 8_MC kb_NN downstream_JJ from_II exon_NN 1b_NN ._.
P02201832A01
A_DD modified_VVNJ polymerase_NN chain_NN reaction_NN (_( PCR_NN )_) procedure_NN was_VBD used_VVN to_TO study_VVI the_DD expression_NN of_II bcr-abl_NN fusion_NN transcripts_NNS following_VVG allogeneic_JJ bone_NN marrow_NN transplantation_NN (_( BMT_NN )_) for_II Philadelphia_NN chromosome_NN (_( Ph1_NN )_) positive_JJ acute_JJ and_CC chronic_JJ leukemias_NNS ._.
P02223646A07
In_II the_DD series_NN analysed_VVN by_II ethidium_NN bromide_NN stained_VVNJ gels_NNS ,_, there_EX was_VBD ,_, however_RR ,_, an_DD increase_NN in_II the_DD percentage_NN of_II cases_NNS expressing_VVG the_DD b3a2_NN junction_NN in_II the_DD mononuclear_JJ cells_NNS of_II blast_NN crisis_NN patients_NNS as_CS compared_VVN to_II the_DD white_JJ blood_NN cells_NNS of_II patients_NNS in_II chronic_JJ phase_NN ._.
P02403827A02
These_DD molecular_JJ phenomena_NNS may_VM occur_VVB even_RR in_II the_DD absence_NN of_II cytogenetic_JJ evidence_NN of_II the_DD Ph_NN translocation_NN ._.
P02407300A04
Cloning_VVGN and_CC sequencing_VVGN of_II the_DD chimeric_JJ part_NN of_II bcr-abl_NN cDNAs_NNS from_II two_MC Ph-positive_JJ CML_NN patients_NNS in_II chronic_JJ phase_NN showed_VVD that_CST in_II one_MC patient_NN ,_, as_CS in_II the_DD Ph-positive_JJ ALL_NN ,_, all_DD central_JJ bcr_NN sequences_NNS are_VBB absent_JJ ,_, while_CS in_II the_DD other_JJ patient_NN ,_, part_NN of_II the_DD bcr_NN central_JJ sequences_NNS are_VBB deleted_VVN ._.
P02684296A04
Seven_MC of_II 13_MC ,_, or_CC 54_MC %_SYM of_II patients_NNS with_II bcr_NN /_SYM abl_NN rearrangement_NN negative_JJ chronic_JJ phase_NN CML_NN (_( atypical_JJ CML_NN )_) harbored_VVD mutations_NNS in_II ras_NN ,_, however_RR ._.
P02730954A03
Among_II the_DD 21_MC samples_NNS obtained_VVN in_II chronic_JJ phase_NN ,_, eight_MC patients_NNS had_VHD the_DD L-6_NN mRNA_NN ,_, 11_MC had_VHD the_DD K-28_NN mRNA_NN ,_, and_CC two_MC had_VHD both_CC the_DD L-6_NN and_CC K-28_NN mRNAs_NNS ._.
P02848601A04
Therefore_RR ,_, it_PN can_VM be_VBB hypothesized_VVN that_CST the_DD transition_NN from_II chronic_JJ to_II blast_NN phase_NN in_II CML_NN is_VBZ accompanied_VVN by_II an_DD alternative_JJ splice_NN in_II the_DD bcr-abl_NN mRNA_NN ,_, which_PNR results_VVZ in_II a_DD switch_NN of_II the_DD production_NN of_II P210bcr-abl_NN into_II P190bcr-abl_NN ._.
P07509222A07
These_DD results_NNS indicated_VVD that_CST normal_JJ clones_NNS can_VM persist_VVB in_II CD34+DR-_NN progenitors_NNS in_II some_DD patients_NNS with_II CML_NN ,_, even_RR when_CS chromosome_NN analysis_NN detects_VVZ the_DD Ph_NN chromosome_NN in_II all_DD metaphases_NNS of_II bone_NN marrow_NN cells_NNS ._.
P07520786A03
Quantification_NN of_II the_DD autoradiographic_JJ signals_NNS of_II amplified_VVNJ products_NNS was_VBD estimated_VVN using_VVG an_DD MCID_NN image_NN analysis_NN system_NN ._.
P07662984A02
Cell_NN lines_NNS established_VVN from_II CML_NN patients_NNS in_II blast_NN crisis_NN show_VVB higher_JJR expression_NN of_II this_DD aberrant_JJ bcr-abl_NN transcript_NN than_CSN cells_NNS from_II patients_NNS in_II chronic_JJ phase_NN of_II the_DD disease_NN ._.
P07701913A03
A_DD sensitive_JJ two-step_NN reverse-transcription_NN polymerase_NN chain_NN reaction_NN (_( RT-PCR_NN )_) was_VBD done_VDN to_TO score_VVI BCR-ABL-mRNA-positive_JJ leukemic_JJ cells_NNS in_II frozen_VVNJ bone_NN marrow_NN samples_NNS of_II 15_MC CML_NN patients_NNS retrospectively_RR ._.
P07817701A01
A_DD patient_NN with_II myasthenia_NN gravis_NN and_CC a_DD thymoma_NN did_VDD not_RR respond_VVB to_II thymectomy_NN ._.
P07857690A08
The_DD products_NNS were_VBD characterized_VVN using_VVG agarose_NN gel_NN electrophoresis_NN ._.
P07938018A01
De_JJ+ novo_JJ methylation_NN of_II CpG_NN islands_NNS is_VBZ a_DD rare_JJ event_NN in_II mammalian_JJ cells_NNS ._.
P07967054A07
Bcr-abl_NN mRNA_NN was_VBD detectable_JJ in_II 6_MC of_II 7_MC cases_NNS (_( 6_MC /_SYM 7_MC )_) within_II 6_MC months_NNS after_II BMT_NN ,_, all_DD five_MC cases_NNS from_II 6_MC months_NNS to_II 1_MC year_NN (_( 1Y_NN )_) ,_, 2_MC /_SYM 8_MC at_II 1Y_NN ,_, 3_MC /_SYM 7_MC at_II 2Y_NN ,_, and_CC 3_MC /_SYM 7_MC over_II 3Y_NN ._.
P08035612A05
In_II each_DD CML_NN patient_NN the_DD incidence_NN of_II '_`` positive_JJ '_'' T_NN cells_NNS was_VBD much_RR less_RR than_CSN in_II positive_JJ controls_NNS and_CC similar_JJ to_II that_PND found_VVN in_II negative_JJ controls_NNS (_( mean_NN values_NNS +/-_SYM 1_MC SD_NN :_: 7.7_MC +/-_SYM 3.6_MC ;_: 91.2_MC +/-_SYM 3.1_MC ,_, and_CC 5.6_MC +/-_SYM 2.2_MC ,_, respectively_RR )_) ._.
P08204887A07
Of_II interest_NN ,_, six_MC Ph1-negative_JJ CML_NN patients_NNS were_VBD BCR-ABL_NN protein-positive_JJ ._.
P08231244A07
Hematological_JJ relapse_NN occurred_VVD in_II five_MC of_II the_DD latter_JJ patients_NNS ._.
P08251917A05
No_DD different_JJ mobility_NN shifts_NNS of_II single_JJ stranded_VVNJ PCR_NN products_NNS were_VBD found_VVN in_II the_DD other_JJ amplified_VVNJ fragments_NNS ._.
P08289478A02
Little_PND is_VBZ known_VVN about_II the_DD mechanism_NN of_II this_DD inhibition_NN ._.
P08295258A06
Both_DD bands_NNS were_VBD seen_VVN more_RR frequently_RR in_II blast_NN crisis_NN than_CSN in_II remission_NN and_CC chronic_JJ phase_NN ._.
P08374529A08
The_DD mean_NN number_NN of_II megakaryocyte_NN progenitor_NN cells_NNS assayed_VVN by_II in_JJ+ vitro_JJ cloning_VVGN was_VBD 128.3_MC /_SYM 2_MC x_SYM 10_MC (_( 5_MC )_) bone_NN marrow_NN cells_NNS for_II 3_MC '_SYM patients_NNS (_( n_NN =_SYM 7_MC )_) compared_VVN with_II 46.3_MC for_II 5_MC '_SYM patients_NNS (_( n_NN =_SYM 4_MC )_) ._.
P08417787A07
Direct_JJ sequencing_VVGN of_II PCR_NN fragments_NNS representing_VVG the_DD full-length_NN coding_VVGJ sequence_NN of_II ABL-BCR_NN cDNAs_NNS type_NN Ib-b3_NN ,_, Ia-b3_NN ,_, Ib-b4_NN ,_, and_CC Ia-b4_NN showed_VVD an_DD open_JJ reading_VVGJ frame_NN predicted_VVN to_TO encode_VVI fusion_NN proteins_NNS of_II 370_MC to_II 414_MC amino-acids_NNS ._.
P08427990A08
If_CS only_RR patients_NNS in_II chronic_JJ phase_NN are_VBB compared_VVN ,_, the_DD t-test_NN showed_VVD significant_JJ correlation_NN between_II leukocyte_NN count_NN just_RR before_II BMT_NN and_CC sustained_VVNJ bcr-abl_NN transcript_NN (_( P_NN <_SYM .05_MC )_) ._.
P08475126A10
The_DD late-onset_NN CML-like_JJ disease_NN and_CC transfer_NN to_II secondary_JJ recipients_NNS provides_VVZ a_DD useful_JJ murine_JJ model_NN with_II features_NNS of_II the_DD chronic_JJ and_CC acute_JJ phases_NNS of_II human_NN CML_NN ._.
P08507874A01
Fluorescence_NN in_JJ+ situ_JJ hybridization_NN (_( FISH_NN )_) has_VHZ become_VVN an_DD increasingly_RR important_JJ method_NN for_II assessing_VVGN chromosome_NN rearrangement_NN ._.
P08542954A07
This_DD ASO_NN had_VHD a_DD hairpin-like_JJ secondary_JJ structure_NN and_CC was_VBD found_VVN to_TO be_VBI much_RR more_RR resistant_JJ to_II the_DD action_NN of_II nucleases_NNS than_CSN control_NN 18-mer_NN standard_JJ oligonucleotides_NNS ._.
P08590842A01
Antisense_NN oligonucleotides_NNS were_VBD used_VVN to_TO determine_VVI the_DD role_NN of_II the_DD BCR-ABL_NN gene_NN in_II the_DD proliferation_NN of_II chronic_JJ myeloid_NN leukaemia_NN (_( CML_NN )_) clonogenic_JJ cells_NNS ._.
P08625225A08
Among_II patients_NNS in_II the_DD early_JJ chronic_JJ phase_NN ,_, thrombocytosis_NN was_VBD significantly_RR associated_VVN with_II the_DD 3_MC '_SYM breakpoint_NN site_NN (_( P_NN =_SYM 0.02_MC )_) ,_, whereas_CS peripheral_JJ basophilia_NN occurred_VVD more_RR frequently_RR with_II the_DD 5_MC '_SYM breakpoint_NN site_NN (_( P_NN =_SYM 0.05_MC )_) ._.
P08639848A07
In_II contrast_NN to_II NL_NN marrow_NN ,_, 34+DR+_NN cells_NNS from_II CML_NN marrow_NN ,_, irrespective_II+ of_II clinical_JJ stage_NN ,_, contained_VVD large_JJ numbers_NNS of_II LTC-IC_NN ._.
P08652835A03
Neither_CC p210_NN nor_CC p190_NN BCR-ABL_NN transcripts_NNS were_VBD detected_VVN in_II normal_JJ healthy_JJ adults_NNS (_( n_NN =_SYM 20_MC )_) ._.
P08656674A04
We_PN analyzed_VVD routine_JJ blood_NN and_CC marrow_NN specimens_NNS from_II eight_MC patients_NNS who_PNR presented_VVD with_II Ph+_NN lymphoblastic_JJ leukemia_NN and_CC found_VVD that_CST FISH_NN recognized_VVD the_DD 9_MC ;_: 22_MC translocation_NN ,_, distinguished_VVD between_II the_DD two_MC common_JJ molecular_JJ variants_NNS ,_, and_CC readily_RR identified_VVD multilineage_NN vs_CC lymphoblast-restricted_VVNJ disease_NN ._.
P08659451A06
Fifty_MC of_II 53_MC pre-BMT_NN samples_NNS were_VBD positive_JJ by_II RT-PCR_NN ._.
P08659451A18
Furthermore_RR ,_, RT-PCR_NN can_VM be_VBB successfully_RR performed_VVN on_II peripheral_JJ blood_NN ,_, yielding_VVG excellent_JJ correlation_NN with_II bone_NN marrow_NN samples_NNS ._.
P08697426A04
This_PND could_VM be_VBB caused_VVN by_II duplication_NN of_II the_DD rearranged_VVNJ chromosome_NN 9_MC ,_, which_PNR may_VM have_VHB a_DD significance_NN similar_JJ to_II a_DD double_JJ Ph_NN chromosome_NN ._.
P08704208A06
Compared_VVN with_II mice_NNS treated_VVN with_II individual_JJ compounds_NNS ,_, the_DD disease_NN process_NN was_VBD significantly_RR retarded_VVN in_II the_DD group_NN treated_VVN with_II both_DD [_( S_NN ]_) ODNs_NNS as_CS revealed_VVN by_II flow_NN cytometry_NN ,_, clonogenic_JJ assay_NN ,_, and_CC RT-PCR_NN analysis_NN to_TO detect_VVI leukemic_JJ cells_NNS in_II mouse_NN tissue_NN cell_NN suspensions_NNS ._.
P08795691A06
The_DD appearance_NN of_II minor_JJ bcr_NN /_SYM abl_NN fusion_NN mRNA_NN was_VBD associated_VVN with_II the_DD lymphoblastic_JJ immunophenotype_NN of_II the_DD blast_NN cells_NNS ._.
P08853030A07
A_DD decreasing_VVGJ ratio_NN was_VBD found_VVN in_II patients_NNS with_II decreasing_VVGJ percentages_NNS of_II Ph_NN ._.
P08874208A06
Analysis_NN of_II individual_JJ CML_NN colonies_NNS for_II the_DD presence_NN of_II the_DD hybrid_NN BCR_NN /_SYM ABL_NN mRNA_NN by_II reverse_JJ transcription-polymerase_NN chain_NN reaction_NN (_( RT-PCR_NN )_) showed_VVD that_CST genistein_NN treatment_NN significantly_RR reduced_VVD the_DD mean_NN +/-_SYM SD_NN percentage_NN of_II marrow_NN BCR_NN /_SYM ABL+_NN progenitors_NNS both_CC by_II continuous_JJ exposure_NN (_( 76_MC %_SYM +/-_SYM 18_MC %_SYM v_NN 24_MC %_SYM +/-_SYM 12_MC %_SYM ,_, P_NN <_SYM or_CC =_SYM .004_MC )_) or_CC preincubation_NN (_( 75_MC %_SYM +/-_SYM 16_MC %_SYM v_NN 21_MC %_SYM +/-_SYM 10_MC %_SYM ,_, P_NN <_SYM or_CC =_SYM .002_MC )_) experiments_NNS ._.
P09028165A03
Either_DD bcr-abl_NN is_VBZ normally_RR expressed_VVN ,_, but_CC both_DD types_NNS of_II bcr-abl_NN mRNA_NN can_VM be_VBB expressed_VVN at_II the_DD same_JJ time_NN in_II a_DD patient_NN ._.
P09168938A03
To_TO elucidate_VVI the_DD mechanism_NN of_II hLH-2_NN transcriptional_JJ activation_NN ,_, we_PN studied_VVD the_DD methylation_NN status_NN of_II hLH-2_NN in_II normal_JJ bone_NN marrow_NN and_CC CML_NN cells_NNS ._.
P09177433A08
Experiments_NNS aimed_VVN at_II evaluating_VVGN the_DD effect_NN of_II the_DD incubation_NN time_NN showed_VVD a_DD significant_JJ increase_NN in_II anti-leukaemic_JJ effect_NN after_II a_DD 120_MC h_NN incubation_NN period_NN compared_VVN to_II that_PND measured_VVN after_II a_DD 24_MC h_NN incubation_NN period_NN ;_: this_PND was_VBD parallelled_VVN by_II a_DD progressive_JJ increase_NN in_II the_DD intracellular_JJ concentrations_NNS of_II [_( S_NN ]_) ODNs_NNS from_II day_NN 1_MC to_II day_NN 5_MC ._.
P09305602A07
Using_VVG fluorescence_NN in_JJ+ situ_JJ hybridization_NN (_( FISH_NN )_) in_II conjunction_NN with_II BCR_NN and_CC ABL_NN probes_NNS we_PN detected_VVD Ph+_NN and_CC Ph-_NN cells_NNS in_II both_CC adherent_JJ and_CC non-adherent_JJ CD34+_NN cell_NN fractions_NNS of_II 15_MC /_SYM 15_MC patients_NNS studied_VVN and_CC in_II the_DD HLA-DR_NN (_( lo_NN )_) or_CC CD38_NN (_( lo_NN )_) sorted_VVNJ CD34+_NN cell_NN fractions_NNS ._.
P09311272A04
Administration_NN of_II hydroxycarbamide_NN was_VBD initiated_VVN ,_, but_CC in_II May_NN she_PN developed_VVD high_JJ fever_NN and_CC severe_JJ left_JJ hypochondralgia_NN ._.
P09389369A01
We_PN present_VVB the_DD case_NN of_II a_DD two-year-old_JJ child_NN with_II an_DD atypical_JJ presentation_NN of_II chronic_JJ myeloid_NN leukemia_NN ._.
P09426513A11
We_PN conclude_VVB the_DD utility_NN of_II FISH_NN and_CC RT-PCR_NN is_VBZ associated_VVN with_II certain_JJ limitations_NNS ,_, such_II+ as_II insufficient_JJ RNA_NN for_II RT-PCR_NN and_CC the_DD occasional_JJ absence_NN of_II internal_JJ positive_JJ FISH_NN control_NN signals_NNS ._.
P09494617A06
The_DD use_NN of_II dual_JJ color_NN FISH_NN in_II the_DD diagnosis_NN of_II CML_NN is_VBZ extremely_RR valuable_JJ not_RR only_RR in_II identifying_VVGN cases_NNS of_II Ph-negative_JJ CML_NN ,_, but_CC also_RR in_II quantifying_VVGN the_DD proportion_NN of_II transformed_VVNJ cell_NN populations_NNS ._.
P09530344A06
The_DD present_JJ case_NN suggests_VVZ that_CST p190_NN BCR_NN /_SYM ABL_NN is_VBZ associated_VVN with_II the_DD aggressive_JJ course_NN of_II the_DD disease_NN ._.
P09613984A04
Of_II the_DD 15_MC patients_NNS ,_, 9_MC are_VBB alive_JJ and_CC in_II complete_JJ remission_NN (_( CR_NN )_) ,_, 4_MC have_VHB died_VVN in_II CR_NN and_CC 2_MC are_VBB alive_JJ but_CC suffered_VVD relapse_NN at_II +_SYM 19_MC and_CC +26_MC months_NNS post-BMT_NN ._.
P09665193A03
FISH_NN detected_VVD 9-16_MC %_SYM nuclei_NNS with_II a_DD BCR-ABL_NN fusion_NN gene_NN ,_, contrasting_VVG with_II RT-PCR_NN ,_, performed_VVN in_II two_MC cases_NNS ,_, which_PNR was_VBD negative_JJ in_II one_MC case_NN and_CC weakly_RR positive_JJ in_II the_DD other_PND ._.
P09808572A07
Analysis_NN of_II the_DD proviral_JJ integration_NN pattern_NN shows_VVZ that_CST ,_, in_II some_DD mice_NNS ,_, the_DD myeloproliferative_JJ disease_NN is_VBZ clonal_JJ ._.
P09834240A04
Furthermore_RR ,_, the_DD 2-5A-antisense_NN chimeras_NNS suppressed_VVD growth_NN of_II K562_NN ,_, while_CS having_VHG substantially_RR reduced_VVNJ effects_NNS on_II the_DD promyelocytic_JJ leukemia_NN cell_NN line_NN ,_, HL60_NN ._.
P09858221A04
We_PN performed_VVD RT-PCR_NN on_II samples_NNS from_II CML_NN patients_NNS in_II chronic_JJ phase_NN to_TO determine_VVI the_DD frequency_NN and_CC mechanism_NN of_II p190_NN and_CC p210_NN co-expression_NN and_CC to_TO see_VVI if_CST this_PND correlated_VVD with_II clinical_JJ indices_NNS ._.
P10087949A04
When_CS promyelocytic_JJ blast_NN crisis_NN was_VBD diagnosed_VVN according_II+ to_II the_DD French-American-British_JJ classification_NN ,_, cytogenetic_JJ studies_NNS revealed_VVD an_DD i_NN (_( 17q_NN )_) as_II a_DD new_JJ feature_NN in_II our_PNG patient_NN ._.
P10200527A06
Inhibition_NN of_II caspase_NN suppressed_VVD apoptosis_NN and_CC the_DD cleavage_NN of_II pRB_NN ,_, and_CC in_II turn_NN arrested_VVD cells_NNS in_II the_DD G1_NN phase_NN ._.
P10222655A07
The_DD literature_NN provides_VVZ support_NN for_II the_DD existence_NN of_II a_DD relationship_NN between_II multiple_JJ myelomas_NNS and_CC CML_NN ._.
P10349111A04
Median_JJ age_NN was_VBD 32_MC years_NNS (_( range_NN 9_MC to_II 47_MC )_) ;_: 15_MC of_II them_PN were_VBD in_II chronic_JJ phase_NN (_( CP_NN )_) ,_, and_CC 4_MC in_II accelerated_VVNJ phase_NN (_( AP_NN )_) ._.
P10374889A09
We_PN used_VVD in_JJ+ situ_JJ RT-PCR_NN by_II comparison_NN to_II cytogenetics_NNS (_( at_RR+ least_RR 30_MC mitoses_NNS examined_VVD )_) ,_, and_CC two-step_NN RT-PCR_NN (_( 10_MC (_( -6_MC )_) sensitivity_NN in_II our_PNG hands_NNS )_) in_II bone_NN marrow_NN samples_NNS from_II 13_MC CML_NN patients_NNS :_: two_MC patients_NNS at_II diagnosis_NN and_CC 11_MC patients_NNS in_II hematological_JJ remission_NN after_II alpha_NN interferon_NN (_( three_MC patients_NNS )_) ,_, hydroxyurea_NN (_( one_MC patient_NN )_) autologous_JJ bone_NN marrow_NN transplantation_NN (_( BMT_NN )_) (_( one_MC patient_NN )_) and_CC allogeneic_JJ BMT_NN (_( six_MC patients_NNS )_) ._.
P10400414A05
Thirty_MC consecutive_JJ Philadelphia_NN (_( Ph_NN )_) chromosome_NN positive_JJ patients_NNS were_VBD enrolled_VVN in_II this_DD study_NN ._.
P10494184A01
Chronic_JJ myelogenous_JJ leukemia_NN is_VBZ characterized_VVN by_II an_DD abnormal_JJ 22nd_JJ chromosome_NN known_VVN as_II a_DD Philadelphia_NN chromosome_NN ,_, which_PNR can_VM be_VBB detected_VVN in_II 95_MC %_SYM of_II patients_NNS with_II CML_NN ._.
P10498589A02
We_PN used_VVD a_DD very_RR sensitive_JJ quantitative_JJ reverse_JJ transcriptase-polymerase_NN chain_NN reaction_NN to_TO investigate_VVI the_DD levels_NNS of_II hybrid_NN BCR_NN /_SYM ABL_NN mRNA_NN in_II bone_NN marrow_NN cells_NNS of_II 20_MC patients_NNS with_II Philadelphia_NN positive_JJ (_( Ph_NN (_( +_SYM )_) )_) CML_NN treated_VVN with_II interferon-alpha_NN (_( IFN-alpha_NN )_) as_II a_DD single_JJ agent_NN ._.
P10509158A03
The_DD Ph_NN chromosome_NN detection_NN via_II fluorescence_NN in_JJ+ situ_JJ hybridization_NN after_II 24-hour_NN mitotic_JJ arrest_NN of_II bone_NN marrow_NN cultures_NNS resulting_VVG in_II several_JJ hundreds_NNS of_II metaphases_NNS (_( hypermetaphase_NN FISH_NN or_CC HMF_NN )_) was_VBD useful_JJ in_II explaining_VVGN the_DD nature_NN of_II the_DD six_MC cases_NNS ._.
P10549264A04
In_II CML_NN patients_NNS with_II clonal_JJ evolution_NN of_II a_DD simple_JJ Ph_NN ,_, a_DD signal_NN of_II the_DD chromosome_NN 22_MC painting_VVGJ probe_NN was_VBD detected_VVN on_II the_DD der_NN (_( 9_MC )_) of_II the_DD Ph_NN translocation_NN ._.
P10602422A02
The_DD e1a2_NN ,_, b2a2_NN or_CC b3a2_NN and_CC c3a2_NN fusion_NN mRNAs_NNS encode_VVB distinct_JJ fusion_NN proteins_NNS (_( p190_NN ,_, p210_NN and_CC p230_NN ,_, respectively_RR )_) ,_, which_PNR are_VBB associated_VVN with_II different_JJ forms_NNS of_II leukemogenesis_NN in_II humans_NNS and_CC animal_NN models_NNS ._.
P10607685A01
A_DD substantial_JJ minority_NN of_II patients_NNS with_II chronic_JJ myelogenous_JJ leukemia_NN (_( CML_NN )_) achieve_VVB a_DD complete_JJ response_NN (_( CR_NN )_) to_II treatment_NN with_II interferon-alpha_NN (_( IFN_NN )_) ,_, defined_VVN as_II the_DD disappearance_NN of_II Philadelphia_NN chromosome-positive_JJ metaphases_NNS ._.
P10607685A13
(_( Blood._NN 2000_MC ;_: 95_MC :_: 62-66_MC )_)
P10629589A05
DESIGN_NN AND_CC METHODS_NNS :_: Dual-color_NN fluorescence_NN in_JJ+ situ_JJ hybridization_NN (_( FISH_NN )_) can_VM visualize_VVB BCR_NN and_CC ABL_NN genes_NNS and_CC localize_VVB the_DD BCR_NN /_SYM ABL_NN fusion_NN gene_NN ._.
P10666183A06
The_DD blast_NN cells_NNS were_VBD clonal_JJ in_II origin_NN and_CC expressed_VVD p210_NN (_( bcr_NN /_SYM abl_NN )_) with_II an_DD increased_VVNJ kinase_NN activity_NN ._.
P10681725A04
Median_JJ follow-up_NN was_VBD 61_MC months_NNS (_( range_NN 4-92_MC )_) ._.
P10985361A04
However_RR ,_, molecular_JJ relapses_NNS of_II CML_NN after_II transplant_NN were_VBD only_RR safely_RR detectable_JJ when_CS a_DD nested_VVNJ real-time_NN PCR_NN assay_NN was_VBD performed_VVN ,_, which_PNR was_VBD able_JJ to_TO detect_VVI 1-10_MC pg_NN cDNA_NN from_II a_DD tenfold_NN serial_JJ dilution_NN ._.
P11091204A08
Neither_CC NK_NN cells_NNS nor_CC T_NN cells_NNS showed_VVD any_DD positive_JJ BCR-ABL_NN signal_NN with_II the_DD exception_NN of_II one_MC patient_NN who_PNR recovered_VVD from_II a_DD lymphoid_JJ blastic_JJ crisis_NN ._.
P11150599A06
In_II this_DD article_NN ,_, we_PN present_VVB several_JJ quality_NN control_NN and_CC assurance_NN methods_NNS that_PNR can_VM be_VBB useful_JJ in_II providing_VVGN standardization_NN of_II the_DD FISH_NN technique_NN ._.
P11175620A06
DIAGNOSTIC_JJ TEST_NN :_: Karyotyping_VVGN was_VBD done_VDN in_II the_DD usual_JJ way_NN and_CC the_DD BCR_NN /_SYM ABL_NN gene-specific_JJ probe_NN was_VBD used_VVN for_II FISH_NN ._.
P11233781A10
In_II blast_NN crisis_NN (_( 6_MC patients_NNS )_) ,_, all_DD colonies_NNS tested_VVN were_VBD BCR-ABL_NN positive_JJ ._.
P11243401A02
We_PN found_VVD a_DD high_JJ proportion_NN of_II 12.51_MC +/-_SYM 1.19_MC %_SYM of_II CD34+_NN peripheral_JJ blood_NN progenitor_NN cells_NNS (_( PBPC_NN )_) in_II S_NN /_SYM G2M_NN phase_NN ._.
P11287973A02
This_DD enzyme_NN is_VBZ present_JJ in_II virtually_RR all_DD cases_NNS of_II chronic_JJ myeloid_NN leukemia_NN (_( CML_NN )_) throughout_II the_DD course_NN of_II the_DD disease_NN ,_, and_CC in_II 20_MC percent_NN of_II cases_NNS of_II acute_JJ lymphoblastic_JJ leukemia_NN (_( ALL_NN )_) ._.
P11387365A09
Only_RR one_MC of_II 26_MC patients_NNS developed_VVD blast_NN crisis_NN ._.
P11691826A04
Inhibition_NN of_II Bcr-Abl_NN with_II STI571_NN resulted_VVD in_II down-regulation_NN of_II cyclin_NN D2_NN and_CC reduction_NN of_II the_DD number_NN of_II cells_NNS in_II S_NN phase_NN ,_, although_CS complete_JJ G1_NN arrest_NN was_VBD not_RR induced_VVN ._.
P11777957A09
p210-enhanced_VVNJ green_JJ fluorescence_NN protein-transduced_VVNJ cells_NNS gave_VVD rise_NN to_II significantly_RR decreased_VVNJ numbers_NNS of_II NK_NN cells_NNS compared_VVN with_II enhanced_VVNJ green_JJ fluorescence_NN protein_NN transduction_NN alone_JJ ._.
P11801312A02
We_PN report_VVB the_DD frequencies_NNS of_II BCR-ABL_NN transcript_NN variants_NNS studied_VVN in_II chronic_JJ myeloid_NN leukemia_NN (_( CML_NN )_) and_CC acute_JJ lymphoblastic_JJ leukemia_NN (_( ALL_NN )_) patients_NNS in_II the_DD Ecuadorian_NN population_NN ._.
P12094246A03
Patients_NNS were_VBD evaluated_VVN for_II hematologic_JJ ,_, cytogenetic_JJ and_CC molecular_JJ response_NN ,_, survival_NN and_CC toxicity_NN ._.
P12100156A03
Sequencing_VVGJ analysis_NN of_II these_DD products_NNS revealed_VVD BCR-ABL_NN fusion_NN transcripts_NNS with_II e19a2_NN in_II patient_NN 1_MC and_CC e191a_NN in_II patient_NN 2_MC ._.
P12200666A06
Cytogenetic_JJ response_NN was_VBD determined_VVN in_II 3-monthly_JJ intervals_NNS :_: From_II 101_MC evaluable_JJ patients_NNS ,_, 42_MC achieved_VVD a_DD complete_JJ (_( CR_NN ,_, 0_MC %_SYM Philadelphia_NN chromosome_NN (_( Ph_NN )_) -_: positive_JJ metaphases_NNS )_) ,_, 18_MC a_DD partial_JJ (_( PR_NN ,_, 1-34_MC %_SYM Ph+_NN )_) ,_, 13_MC a_DD minor_JJ (_( MR_NN ,_, 35-94_MC %_SYM Ph+_NN )_) ,_, and_CC 26_MC no_DD response_NN (_( NR_NN ,_, >_SYM 94_MC %_SYM Ph+_NN )_) ._.
P12351420A01
Clinical_JJ resistance_NN to_II imatinib_NN mesylate_NN is_VBZ commonly_RR observed_VVN in_II patients_NNS with_II advanced_VVNJ Philadelphia_NN chromosome-_NN positive_JJ (_( Ph_NN (_( +_SYM )_) )_) leukemias_NNS ._.